| Drug NDC: | 62795-1042 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. | |
| Proprietary Name: | Reboost |
| Also known as the trade name. It is the name of the product chosen by the labeler. | |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. | |
| Non Proprietary Name: | Aconitum Napellus, Bryonia Alba Root, Eupatorium Perfoliatum Flowering Top, Goldenseal, Lachesis Muta Venom, Phosphorus, Vincetoxicum Hirundinaria Root, Zinc Gluconate, Zinc Acetate Anhydrous, Cairina Moschata Heart/liver Autolysate, Ipecac, Sulfur And Influenza A Virus A/singapore/6/86 (h1n1) Antigen (heat Inactivated) |
| Also known as the generic name, this is usually the active ingredient(s) of the product. | |
| Labeler Name: | Medinatura Inc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. | |
| Dosage Form: | Tablet |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. | |
| Substance Name: | ACONITUM NAPELLUS - 3 [hp_X]/1 BRYONIA ALBA ROOT - 3 [hp_X]/1 CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE - 20 [hp_X]/1 EUPATORIUM PERFOLIATUM FLOWERING TOP - 6 [hp_X]/1 GOLDENSEAL - 5 [hp_X]/1 INFLUENZA A VIRUS A/SINGAPORE/6/86 (H1N1) ANTIGEN (HEAT INACTIVATED) - 19 [hp_X]/1 IPECAC - 3 [hp_X]/1 LACHESIS MUTA VENOM - 10 [hp_X]/1 PHOSPHORUS - 8 [hp_X]/1 SULFUR - 4 [hp_X]/1 Load more... VINCETOXICUM HIRUNDINARIA ROOT - 6 [hp_X]/1 ZINC ACETATE ANHYDROUS - 2 [hp_X]/1 ZINC GLUCONATE - 1 [hp_X]/1 |
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. | |
| Route Details: | ORAL |
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Category: | UNAPPROVED HOMEOPATHIC |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. | |
| Marketing Start Date: | 19 Feb, 2020 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. | |
| Marketing End Date: | 30 Apr, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. | |
| Listing Expiration Date: | 25 Jun, 2026 |
| This is the date when the listing record will expire if not updated or certified by the firm. | |
| Manufacturer Name: | MediNatura Inc. |
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. | |
| Original Packager: | Yes |
| Whether or not the drug has been repackaged for distribution. | |
| UNII: | U0NQ8555JD T7J046YI2B RN2HC612GY 1W0775VX6E ZW3Z11D0JV WC4E824FQ9 62I3C8233L VSW71SS07I 27YLU75U4W 70FD1KFU70 Load more... 9R858U917W H2ZEY72PME U6WSN5SQ1Z |
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. | |
| Pharmacologic Class: | Copper Absorption Inhibitor [EPC] Decreased Copper Ion Absorption [PE] |
| These are the reported pharmacological class categories corresponding to the SubstanceNames listed above. | |
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|---|---|---|---|
| 62795-1042-2 | 1 BOTTLE in 1 CARTON (62795-1042-2) / 60 TABLET in 1 BOTTLE | 19 Feb, 2020 | 30 Apr, 2025 | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. | ||||
* Data of this site is collected from www.fda.gov. This page is for informational purposes only. Always consult your physician with any questions you may have regarding a medical condition.